

PRESS RELEASE

Zurich, 27 September 2018

DR DANIEL LIEDTKE TO BE APPOINTED CEO OF HIRSLANDEN

Mediclinic International plc, the international private healthcare services group, today announces that its Swiss operating division, Hirslanden, has appointed Dr Daniel Liedtke as successor to Chief Executive Officer, Dr Ole Wiesinger. After more than ten years successfully leading Hirslanden and establishing the business as the leading private hospital group in Switzerland, Dr Ole Wiesinger will be retiring from his role on 1 January 2019, following a hand over period.

Dr Liedtke, 48, joined Hirslanden in 2001 and has subsequently held several senior roles within the business. He was Deputy Director at Hirslanden Klinik St. Anna in Luzern, before becoming Hospital Director of Klinik Hirslanden in Zurich between 2008 to 2015. In 2015, he was appointed to the Hirslanden Executive Committee as Chief Operating Officer, playing an instrumental role in the successful leadership of the business including the implementation of the ongoing Hirslanden 2020 strategic programme. Dr Liedtke is an expert on the Swiss healthcare system and has a proven track record in the development of new business models in the clinical environment. The appointment follows a comprehensive assessment process led by Mediclinic International Executives and Board members, who were unanimous in their decision to appoint Dr Liedtke, and demonstrates the strength of senior management across the Group.

Under Dr Wiesinger's leadership, Hirslanden expanded its footprint from 13 hospitals in 2007 to the current portfolio of 18 hospitals through a series of successful acquisitions, the latest being Klinik Linde in Biel and Clinique des Grangettes in Geneva. Hirslanden now operates four outpatient clinics and has expanded in the fields of radiology and radiotherapy to broaden the overall service offering to patients in Switzerland. During Ole Wiesinger's ten-year term in office, turnover increased from CHF 1091 million to CHF 1735 million, and the number of employees rose from 5224 to 9635 during the same period. Significant investment has been made to enhance the quality of patient care which, together with the support from doctors, clinical staff and other employees, has enabled Hirslanden to retain its leading position in the Swiss private healthcare market. Dr Wiesinger will continue to provide support to the business until the end of March 2019.

Commenting today, Dr Ronnie van der Merwe, Chief Executive Officer of Mediclinic International said:

"On behalf of Mediclinic International and Hirslanden, I would like to express my sincere thanks to Ole for the many years he has dedicated to Hirslanden and for his outstanding leadership of the business. We wish him every success in his future as he explores new opportunities. I am very pleased to welcome Dr Daniel Liedtke as the new CEO of Hirslanden. He has demonstrated an impressive track record and in-depth knowledge of our Swiss business and the local healthcare market. His detailed involvement in the current Hirslanden 2020 strategic programme and understanding of our core business makes him the ideal person to continue the implementation of the programme and lead the business. We welcome his enthusiastic and energetic approach on the Mediclinic International Executive Committee as we work together to deliver long term success across the Group."

Dr Ole Wiesinger, CEO of Hirslanden, commented:

"I look back on the successful career I have had at Hirslanden and I would like to take this opportunity to thank the many talented people who I have worked alongside, during my time at Hirslanden, especially our almost 10,000 employees and 2,000 doctors. I feel that now is the right time to begin a new chapter. It has always been important to me to give back some of the success and experiences from my career and I hope to do this in the future through seeking professional opportunities such as board of director mandates, teaching posts and continuing engagement in a number of charitable endeavors. I wish my

PRESS RELEASE

successor, Dr Daniel Liedtke, the same warm welcome inside and outside the company that I experienced and know from working closely with him for the past ten years that he is capable of achieving great success as CEO of Hirslanden.“

Dr Daniel Liedtke, COO of Hirslanden, commented:

"I am delighted to be taking on the role of Chief Executive Officer at Hirslanden, having spent 17 years working with the excellent team of doctors, clinical staff and employees, as Chief Operating Officer and in other roles. The team delivers best-in-class performance for patients every day, making Hirslanden not only the leading private healthcare group in Switzerland but recognised internationally for the quality of its clinical care. In the role, I will, as Ole has done successfully, seek to build on this position of strength as we navigate through the current regulatory environment and ensure the successful deployment of the Hirslanden 2020 strategic programme.“

Further information:

Hirslanden Private Hospital Group
Frank Nehlig, Head of Corporate Communications
Boulevard Lilienthal 2
8152 Glattpark
T +41 44 388 75 85
medien@hirslanden.ch
www.hirslanden.ch

As of 31 March 2018, the Hirslanden Private Hospital Group consists of 17 hospitals in 11 cantons, many of which have an integrated outpatient surgery centre and emergency department. The Group also operates 4 outpatient clinics, 16 radiology institutes and 4 radiotherapy institutes. It has around 1,680 affiliated doctors and 9,635 permanent employees, 461 of whom are doctors. Hirslanden is the leading private hospital group and the largest medical network in Switzerland. In the 2017/18 financial year, it generated a turnover of 1,735 million Swiss francs. As of 31 March 2018, the Group had treated over 102,903 inpatients with a total of 473 343 inpatient days. In insurance terms, the patient mix consists of 47.9% with basic, 29.7% with semi-private and 22.4% with private insurance.

Hirslanden Private Hospital Group stands for first class medical quality, made possible with highly qualified, experienced doctors. In medical terms, Hirslanden stands out in the market as a system provider. Interdisciplinary medical competence centres and specialist institutes enable optimal and individual treatment of cases, whatever their level of medical complexity. The private hospital group was formed in 1990 out of the merger of a number of private hospitals, and became part of the international hospital group Mediclinic International plc in 2007, which is listed on the London Stock Exchange.